RT Journal
A1 Kan, Zhengyan
A1 Zheng, Hancheng
A1 Liu, Xiao
A1 Li, Shuyu
A1 Barber, Thomas D.
A1 Gong, Zhuolin
A1 Gao, Huan
A1 Hao, Ke
A1 Willard, Melinda D.
A1 Xu, Jiangchun
A1 Hauptschein, Robert
A1 Rejto, Paul A.
A1 Fernandez, Julio
A1 Wang, Guan
A1 Zhang, Qinghui
A1 Wang, Bo
A1 Chen, Ronghua
A1 Wang, Jian
A1 Lee, Nikki P.
A1 Zhou, Wei
A1 Lin, Zhao
A1 Peng, Zhiyu
A1 Yi, Kang
A1 Chen, Shengpei
A1 Li, Lin
A1 Fan, Xiaomei
A1 Yang, Jie
A1 Ye, Rui
A1 Ju, Jia
A1 Wang, Kai
A1 Estrella, Heather
A1 Deng, Shibing
A1 Wei, Ping
A1 Qiu, Ming
A1 Wulur, Isabella H.
A1 Liu, Jiangang
A1 Ehsani, Mariam E.
A1 Zhang, Chunsheng
A1 Loboda, Andrey
A1 Sung, Wing Kin
A1 Aggarwal, Amit
A1 Poon, Ronnie T.
A1 Fan, Sheung Tat
A1 Wang, Jun
A1 Hardwick, James
A1 Reinhard, Christoph
A1 Dai, Hongyue
A1 Li, Yingrui
A1 Luk, John M.
A1 Mao, Mao
T1 Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
JF Genome Research 
JO Genome Research 
YR 2013 
FD September 01 
VO 23 
IS 9 
SP 1422 
OP 1433 
DO 10.1101/gr.154492.113 
UL http://genome.cshlp.org/content/23/9/1422.abstract 
AB Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole-genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta-catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). The Wnt/beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases, respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides a path toward therapeutic intervention of the disease.